Alcon (ALC) Q2 2026 earnings summary

Executive summary

• Q2 2026 sales reached $2.8 billion, up 8% reported and 7% constant currency year-over-year, driven by innovation, new product launches, and strong performance in both Surgical and Vision Care segments.

• UNITY equipment and PanOptix Pro IOL saw rapid adoption, with PanOptix Pro now representing 90% of PanOptix implants in the U.S. and international rollout underway.

• Contact lens business achieved record global market share, led by strong U.S. growth and successful launches in dailies and reusables.

• Discontinued PowerVision IOL programs due to clinical issues, resulting in a $402–$505 million pre-tax, non-cash charge and significant impact on reported earnings.

• Returned $538 million to shareholders year-to-date via dividends and share repurchases, with a new $1.5 billion repurchase program authorized.

Financial highlights

• Q2 2026 net sales: $2.8 billion (+8% YoY); Surgical: $1.6 billion (+8%), Vision Care: $1.2 billion (+8%).

• Core operating income for Q2 was $574 million (20.6% margin, +1.5–1.6 ppts YoY); reported operating income was $11 million, reflecting PowerVision charges.

• Core diluted EPS was $0.84 (+9%–11% YoY); reported diluted EPS was $0.00 due to PowerVision charges.

• Q2 gross margin improved to 60.2% (up from 53.9%); core gross margin was 64.7%.

• Free cash flow for H1 was $693 million; net cash from operating activities was $928 million.

Outlook and guidance

• Maintains 2026 constant currency sales growth guidance of 5%–7%, with core operating margin expansion of 90–190 bps and core diluted EPS growth of 12%–15%.

• Full-year core effective tax rate expected at ~20%.

• Tariffs expected to impact cost of sales by $40–$90 million, with a $60 million refund anticipated in Q3, most of which will be reinvested in growth initiatives.

• Launches of TRYPTYR, Valeda, UNITY CS, and PanOptix Pro in Europe expected to drive H2 growth.

• New $1.5 billion share repurchase program authorized, to be funded by operating cash flow.